JP2021511803A5 - - Google Patents

Info

Publication number
JP2021511803A5
JP2021511803A5 JP2020541767A JP2020541767A JP2021511803A5 JP 2021511803 A5 JP2021511803 A5 JP 2021511803A5 JP 2020541767 A JP2020541767 A JP 2020541767A JP 2020541767 A JP2020541767 A JP 2020541767A JP 2021511803 A5 JP2021511803 A5 JP 2021511803A5
Authority
JP
Japan
Prior art keywords
vector
pharmaceutical composition
composition according
grna
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511803A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015988 external-priority patent/WO2019152609A1/en
Publication of JP2021511803A publication Critical patent/JP2021511803A/ja
Publication of JP2021511803A5 publication Critical patent/JP2021511803A5/ja
Pending legal-status Critical Current

Links

JP2020541767A 2018-01-31 2019-01-31 ヒト心筋細胞におけるジストロフィン変異を修正するための組成物および方法 Pending JP2021511803A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624748P 2018-01-31 2018-01-31
US62/624,748 2018-01-31
PCT/US2019/015988 WO2019152609A1 (en) 2018-01-31 2019-01-31 Compositions and methods for correcting dystrophin mutations in human cardiomyocytes

Publications (2)

Publication Number Publication Date
JP2021511803A JP2021511803A (ja) 2021-05-13
JP2021511803A5 true JP2021511803A5 (cg-RX-API-DMAC7.html) 2022-01-27

Family

ID=65657512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541767A Pending JP2021511803A (ja) 2018-01-31 2019-01-31 ヒト心筋細胞におけるジストロフィン変異を修正するための組成物および方法

Country Status (11)

Country Link
US (1) US20200370042A1 (cg-RX-API-DMAC7.html)
EP (1) EP3746557A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021511803A (cg-RX-API-DMAC7.html)
KR (1) KR20200116933A (cg-RX-API-DMAC7.html)
CN (1) CN111836893A (cg-RX-API-DMAC7.html)
AU (1) AU2019216321A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020015617A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088547A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091828A1 (cg-RX-API-DMAC7.html)
IL (1) IL276139A (cg-RX-API-DMAC7.html)
WO (1) WO2019152609A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3443081A4 (en) 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
TW202100748A (zh) * 2019-04-14 2021-01-01 美國公爵大學 恢復肌縮蛋白功能之基於crispr/cas之基因組編輯組合物
TWI887234B (zh) 2019-04-14 2025-06-21 美國公爵大學 治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除
WO2021064162A1 (en) * 2019-10-02 2021-04-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treatment of diseases caused by frame shift mutations
EP4069314A4 (en) * 2019-12-03 2024-06-26 Duke University SYSTEMS AND METHODS FOR LIPID NANOPARTICLE DELIVERY OF GENE EDITING MACHINERY
JP2023507174A (ja) * 2019-12-16 2023-02-21 プレジデント アンド フェローズ オブ ハーバード カレッジ Dmd変異の修正のための方法及び組成物
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CN115011598A (zh) 2020-09-02 2022-09-06 西湖大学 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用
WO2022081612A1 (en) * 2020-10-12 2022-04-21 Duke University Crispr/cas-based base editing composition for restoring dystrophin function
EP4301462A1 (en) * 2021-03-04 2024-01-10 Research Institute at Nationwide Children's Hospital Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications
AU2022262420A1 (en) * 2021-04-23 2023-11-16 Research Institute At Nationwide Children's Hospital Products and methods for treating muscular dystrophy
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
WO2023039444A2 (en) * 2021-09-08 2023-03-16 Vertex Pharmaceuticals Incorporated Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
WO2023172926A1 (en) * 2022-03-08 2023-09-14 Vertex Pharmaceuticals Incorporated Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
TW202345911A (zh) * 2022-03-08 2023-12-01 美商維泰克斯製藥公司 用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除
WO2023172116A1 (ko) * 2022-03-10 2023-09-14 주식회사 진코어 듀센 근이영양증 치료를 위한 유전자 편집 시스템 및 이를 이용한 질병 치료 방법
WO2023240157A2 (en) * 2022-06-08 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of dmd

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
EP3133160B1 (en) * 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
CA2758189C (en) * 2009-04-10 2020-12-29 Association Institut De Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
HK1220154A1 (zh) * 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
US20160058889A1 (en) * 2014-08-11 2016-03-03 The Board Of Regents Of The University Of Texas System Prevention of muscular dystrophy by crispr/cas9-mediated gene editing
CA2981508A1 (en) * 2015-04-01 2016-10-06 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
EP3332008A4 (en) * 2015-09-23 2019-01-16 Université Laval CHANGE OF THE DYSTROPHINE GENE AND USES THEREOF
JP2018530560A (ja) * 2015-10-09 2018-10-18 サレプタ セラピューティクス, インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
WO2017193029A2 (en) * 2016-05-05 2017-11-09 Duke University Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy
US20190330626A1 (en) * 2016-07-15 2019-10-31 Ionis Pharmaceuticals, Inc. Compounds and methods for use in dystrophin transcript
JP7490211B2 (ja) * 2016-07-19 2024-05-27 デューク ユニバーシティ Cpf1に基づくゲノム編集の治療適用
RU2625003C1 (ru) * 2016-10-04 2017-07-11 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" Набор последовательностей нуклеотидов для медицинской технологии детекции наиболее частых в россии делеций гена dmd методом мультиплексного пцр/пдаф анализа
US10687520B2 (en) * 2017-03-07 2020-06-23 The Board Of Regents Of The University Of Texas System Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44

Similar Documents

Publication Publication Date Title
JP7374119B2 (ja) 減少した肝臓向性を有するAAV9とAAVrh74とのハイブリッド組換えアデノ随伴ウイルス血清型
EP4211231B1 (en) Peptide-modified aav capsid
CN115023242B (zh) 腺相关病毒载体变体
CN105579465B (zh) 用于基因转移到细胞、器官和组织中的变异aav和组合物、方法及用途
JP6619454B2 (ja) キャプシド
JP2022508182A5 (cg-RX-API-DMAC7.html)
BR112020021903A2 (pt) terapia genética para degeneração do snc
JP2021512649A5 (cg-RX-API-DMAC7.html)
JP2020503869A5 (cg-RX-API-DMAC7.html)
JP2019522461A (ja) デュシェンヌ型筋ジストロフィーを治療するためのcrispr/cas関連の方法および組成物
JP2020509786A5 (cg-RX-API-DMAC7.html)
TW201629225A (zh) 第九因子基因療法
JP2020054367A (ja) 改変g6pcをコードするアデノ随伴ウイルスベクターおよびその使用
EP4536686B1 (en) Peptide-modified aav capsid with enhanced muscle transduction efficiency
EP3952920A1 (en) Hybrid promoters for muscle expression
JP2023515795A5 (cg-RX-API-DMAC7.html)
US20230272428A1 (en) Methods and compositions for correction of dmd mutations
KR20250120301A (ko) 심장 질환 및 심장 기능 장애 관련 질환 치료를 위해 간 친화성 감소 및 심장 세포 형질도입이 향상된 재조합-아데노 관련 바이러스 유전자 치료 벡터
KR102874560B1 (ko) 아데노연관바이러스 변이체
US20240398985A1 (en) Novel transcription factors
US12480098B1 (en) Adeno-associated virus variant
WO2026041758A1 (en) Modified aav capsid with enhanced transduction efficiency
BR112023004176B1 (pt) Proteína de capsídeo de aav, polinucleotídeo, plasmídeo recombinante, partícula de vetor de aav, seu uso para tratamento de doenças musculares e composição farmacêutica
HK40091751A (en) Peptide-modified aav capsid